Differentiation syndrome with lower-intensity treatments for acute myeloid leukemia

Amir T. Fathi; Eytan M. Stein; Courtney D. DiNardo; Mark J. Levis; Pau Montesinos; Stéphane de Botton

doi:10.1002/ajh.26142

Differentiation syndrome with lower-intensity treatments for acute myeloid leukemia

Amir T. Fathi, Eytan M. Stein, Courtney D. DiNardo, Mark J. Levis, Pau Montesinos, Stéphane de Botton

Leukemia

Research output: Contribution to journal › Review article › peer-review

12 Scopus citations

Abstract

Differentiation Syndrome (DS) has been identified in a subset of patients undergoing treatment with novel classes of differentiating therapies for acute myeloid leukemia (AML) such as IDH and FLT3 inhibitors. While DS is a well-known treatment-related complication in acute promyelocytic leukemia (APL), efforts are still ongoing to standardize diagnostic and treatment parameters for DS in AML. Though the rates of incidence vary, many of the signs and symptoms of DS are common between APL and AML. So, DS can lead to fatal complications in AML, but prompt management is usually effective and rarely necessitates interruption or discontinuation of AML therapy.

Original language	English (US)
Pages (from-to)	735-746
Number of pages	12
Journal	American journal of hematology
Volume	96
Issue number	6
DOIs	https://doi.org/10.1002/ajh.26142
State	Published - Jun 1 2021

ASJC Scopus subject areas

Hematology

Access to Document

10.1002/ajh.26142

Cite this

@article{d5f565e1107a4116951bf5b07210efcd,

title = "Differentiation syndrome with lower-intensity treatments for acute myeloid leukemia",

abstract = "Differentiation Syndrome (DS) has been identified in a subset of patients undergoing treatment with novel classes of differentiating therapies for acute myeloid leukemia (AML) such as IDH and FLT3 inhibitors. While DS is a well-known treatment-related complication in acute promyelocytic leukemia (APL), efforts are still ongoing to standardize diagnostic and treatment parameters for DS in AML. Though the rates of incidence vary, many of the signs and symptoms of DS are common between APL and AML. So, DS can lead to fatal complications in AML, but prompt management is usually effective and rarely necessitates interruption or discontinuation of AML therapy.",

author = "Fathi, {Amir T.} and Stein, {Eytan M.} and DiNardo, {Courtney D.} and Levis, {Mark J.} and Pau Montesinos and {de Botton}, St{\'e}phane",

note = "Funding Information: The authors received editorial support during manuscript development from Jason Rogers (Medical Communication Company, Inc.), funded by Bristol-Myers Squibb Company. The authors directed manuscript development and are fully responsible for all content and editorial decisions. Publisher Copyright: {\textcopyright} 2021 Wiley Periodicals LLC.",

year = "2021",

month = jun,

day = "1",

doi = "10.1002/ajh.26142",

language = "English (US)",

volume = "96",

pages = "735--746",

journal = "American journal of hematology",

issn = "0361-8609",

publisher = "Wiley-Liss Inc.",

number = "6",

}

TY - JOUR

T1 - Differentiation syndrome with lower-intensity treatments for acute myeloid leukemia

AU - Fathi, Amir T.

AU - Stein, Eytan M.

AU - DiNardo, Courtney D.

AU - Levis, Mark J.

AU - Montesinos, Pau

AU - de Botton, Stéphane

N1 - Funding Information: The authors received editorial support during manuscript development from Jason Rogers (Medical Communication Company, Inc.), funded by Bristol-Myers Squibb Company. The authors directed manuscript development and are fully responsible for all content and editorial decisions. Publisher Copyright: © 2021 Wiley Periodicals LLC.

PY - 2021/6/1

Y1 - 2021/6/1

N2 - Differentiation Syndrome (DS) has been identified in a subset of patients undergoing treatment with novel classes of differentiating therapies for acute myeloid leukemia (AML) such as IDH and FLT3 inhibitors. While DS is a well-known treatment-related complication in acute promyelocytic leukemia (APL), efforts are still ongoing to standardize diagnostic and treatment parameters for DS in AML. Though the rates of incidence vary, many of the signs and symptoms of DS are common between APL and AML. So, DS can lead to fatal complications in AML, but prompt management is usually effective and rarely necessitates interruption or discontinuation of AML therapy.

AB - Differentiation Syndrome (DS) has been identified in a subset of patients undergoing treatment with novel classes of differentiating therapies for acute myeloid leukemia (AML) such as IDH and FLT3 inhibitors. While DS is a well-known treatment-related complication in acute promyelocytic leukemia (APL), efforts are still ongoing to standardize diagnostic and treatment parameters for DS in AML. Though the rates of incidence vary, many of the signs and symptoms of DS are common between APL and AML. So, DS can lead to fatal complications in AML, but prompt management is usually effective and rarely necessitates interruption or discontinuation of AML therapy.

UR - http://www.scopus.com/inward/record.url?scp=85102636513&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85102636513&partnerID=8YFLogxK

U2 - 10.1002/ajh.26142

DO - 10.1002/ajh.26142

M3 - Review article

C2 - 33625753

AN - SCOPUS:85102636513

SN - 0361-8609

VL - 96

SP - 735

EP - 746

JO - American journal of hematology

JF - American journal of hematology

IS - 6

ER -

Differentiation syndrome with lower-intensity treatments for acute myeloid leukemia

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this